GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Daewon Pharmaceutical Co 003220.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

7,770

0.00%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩605.43bn

FY2016FY2025

Net income

−₩1.38bn

FY2016FY2025

Free cash flow

₩181.9m

FY2016FY2025

Shareholders' equity

₩265.92bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩605.43bn₩598.16bn₩526.95bn₩478.88bn₩354.18bn₩308.50bn₩317.83bn₩286.65bn₩265.46bn₩240.72bn
Gross profit₩272.79bn₩287.33bn₩257.25bn₩237.94bn₩176.47bn₩165.94bn₩180.16bn₩165.49bn₩152.04bn₩137.51bn
Research and development₩23.76bn₩21.93bn₩18.21bn₩12.65bn₩12.60bn₩13.48bn₩10.24bn₩9.28bn₩6.76bn₩6.63bn
Operating income₩3.51bn₩28.22bn₩32.23bn₩43.01bn₩19.43bn₩24.10bn₩35.01bn₩30.64bn₩25.29bn₩29.15bn
Net income−₩1.38bn₩14.21bn₩23.92bn₩31.94bn₩6.99bn₩17.64bn₩27.29bn₩23.74bn₩10.74bn₩20.24bn
Diluted earnings per share-0.697.1211.9916.023.508.8413.6811.90576.8810.15

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩613.65bn₩583.39bn₩508.00bn₩453.55bn₩429.58bn₩335.21bn₩327.53bn₩275.44bn₩227.20bn₩214.68bn
Total liabilities₩339.07bn₩298.81bn₩243.73bn₩204.78bn₩211.18bn₩122.44bn₩123.32bn₩92.24bn₩59.07bn₩52.67bn
Debt₩82.87bn₩63.63bn₩34.57bn₩52.12bn₩69.62bn₩28.50bn₩50.00bn₩28.00bn₩10.00bn—
Shareholders' equity₩265.92bn₩275.28bn₩266.20bn₩250.95bn₩219.30bn₩213.94bn₩204.94bn₩183.51bn₩167.99bn₩161.40bn
Shares outstanding1,994m1,994m1,994m1,994m1,994m1,994m1,994m1,995m19m1,995m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩42.31bn₩30.04bn₩51.73bn₩33.33bn₩22.41bn₩24.95bn₩30.97bn₩40.03bn₩4.27bn₩20.79bn
Capital spending−₩42.13bn−₩53.58bn−₩20.61bn−₩13.37bn−₩4.10bn−₩11.35bn−₩33.03bn−₩40.82bn−₩14.71bn−₩20.57bn
Free cash flow₩181.9m−₩23.55bn₩31.12bn₩19.96bn₩18.31bn₩13.61bn−₩2.05bn−₩785.0m−₩10.45bn₩219.0m
Dividends paid−₩6.43bn−₩6.36bn−₩7.34bn−₩4.12bn−₩3.14bn−₩5.03bn−₩4.89bn−₩4.66bn−₩4.52bn−₩3.40bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩152.83bn₩158.06bn₩159.81bn₩143.94bn₩143.86bn₩157.83bn₩145.07bn₩156.83bn
Gross profit₩70.87bn₩75.08bn₩73.57bn₩61.11bn₩63.39bn₩74.73bn₩67.78bn₩75.18bn
Operating income₩6.75bn₩4.38bn₩5.88bn−₩10.20bn−₩1.54bn₩9.41bn₩3.22bn₩10.55bn
Net income₩4.03bn₩2.42bn₩13.60bn−₩17.41bn−₩2.98bn₩5.42bn−₩1.06bn₩6.79bn
Diluted earnings per share2.021.216.82-8.73-1.502.72-0.533.40
Cash from operations−₩4.39bn₩9.21bn₩30.61bn−₩17.25bn₩21.38bn₩7.57bn₩31.15bn₩19.98bn
Capital spending−₩4.15bn−₩11.26bn−₩13.07bn−₩9.67bn−₩11.15bn−₩8.24bn−₩14.60bn−₩22.54bn
Free cash flow−₩8.54bn−₩2.05bn₩17.54bn−₩26.92bn₩10.23bn−₩670.0m₩16.55bn−₩2.56bn
Total assets₩573.33bn₩595.99bn₩613.65bn₩606.37bn₩581.37bn₩598.65bn₩583.39bn₩598.69bn
Debt₩59.53bn₩82.31bn₩82.87bn₩80.09bn₩57.94bn₩60.70bn₩63.63bn₩66.81bn
Shareholders' equity₩267.68bn₩262.84bn₩265.92bn₩256.19bn₩271.70bn₩274.08bn₩275.28bn₩279.03bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.1%14.4%10.8%
Operating income-56.6%-32.0%-17.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin46.5%47.8%48.7%51.2%
Operating margin2.6%4.8%5.2%7.0%
Net margin1.1%3.1%3.2%4.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-17275.2———————30.6—
Price to sales39.447.559.378.191.0116.097.598.01.2130.9

Dividends and splits

Per share, in the currency the company pays

Paid for 26 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year550.00300.00350.00194.175147.943233.405226.607215.816
  • 103-for-100 split · 7 Mar 2022
  • 21-for-20 split · 18 Feb 2021
  • 1.03-for-1 split · 17 Feb 2020
  • 1.03-for-1 split · 11 Feb 2019
  • 21-for-20 split · 19 Feb 2018
  • 1.03-for-1 split · 7 Feb 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.